Binod Dhakal

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 150 citations · Full text

Medicine, Internal Medicine, Oncology +12

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesús G. Berdeja, Tara B. Gregory et al. · Blood · 2022 · 53 citations

Medicine, Pharmacology, Pharmacotherapy +13

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji Kumar, Melissa Alsina, Betsy LaPlant et al. · Blood · 2022 · 40 citations

Medicine, Oncology, Pharmacotherapy +15

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Natalie S. Callander, Rebecca Silbermann, Jonathan L. Kaufman et al. · Blood · 2022 · 20 citations

Medicine, Hematology, Oncology +17

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Ciara Louise Freeman, Binod Dhakal, Gurbakhash Kaur et al. · Blood · 2024 · 18 citations · Full text

Medicine, Hematology, Oncology +9